In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 0.78 below Seres Therapeutics Inc average.

Within Major Pharmaceutical Preparations industry 370 other companies have achieved higher Quick Ratio than Seres Therapeutics Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 1469 to 2193.

Explain Quick Ratio?
How much Cash & cash equivalents MCRB�s has?
What are MCRB�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

MCRB Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	-35.26 %	-38.24 %	-53.13 %	-65.4 %	-71.43 %
Y / Y Cash & cash equivalent Change	-65.64 %	-49.3 %	48.62 %	-28.71 %	-36.29 %
Quick Ratio MRQ	0.78	1.54	2.37	2.12	1.47
MCRB's Total Ranking	# 2193	# 1469	# 1089	# 1055	# 1130
Seq. Current Liabilities Change	3.55 %	0.11 %	-13.85 %	-27.51 %	-1.22 %
Seq. Cash & cash equivalent Change	-47.73 %	-34.81 %	-3.93 %	4.98 %	-22.89 %

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 371
Healthcare Sector	# 674
Overall Market	# 2193

Quick Ratio Statistics
High	Average	Low
56.71	12.6	0.66
(Dec 31 2020)		(Jun 30 2024)

Financial Statements
Seres Therapeutics Inc 's Current Liabilities	$ 20 Millions	Visit MCRB's Balance sheet
Seres Therapeutics Inc 's Cash & cash equivalent	$ 16 Millions	Visit MCRB's Balance sheet
Source of MCRB's Sales		Visit MCRB's Sales by Geography

Cumulative Seres Therapeutics Inc 's Quick Ratio

MCRB's Quick Ratio for the trailling 12 Months

MCRB Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-51.8 %	-62.54 %	-67.04 %	-66.25 %	-56.56 %
Y / Y Cash & cash equivalent TTM Growth	-31.22 %	-25.95 %	-29.43 %	-51.58 %	-57.97 %
Quick Ratio TTM	1.71	1.83	1.9	1.45	1.2
Total Ranking TTM	# 3849	# 3916	# 3023	# 3260	# 2878
Seq. Current Liabilities TTM Growth	-11.85 %	-11.52 %	-17.39 %	-25.19 %	-31.48 %
Seq. Cash & cash equivalent TTM Growth	-17.66 %	-14.68 %	8.2 %	-9.51 %	-11.35 %

Quick ratio ranking by company, industry and sector >> Back to MCRB Financial Strength Comparisons >> Go to Compare MCRB Quick Ratio to its Competitors

News about Seres Therapeutics Inc Quick Ratio

Seres Therapeutics Makes Significant Capital Infusions, Retires Debt, and Extends Cash Runway Into 2025

Seres Therapeutics, a leading microbiome therapeutics company, has announced its plans to secure capital infusions that will enable the company to retire its debt completely and extend its cash runway into the fourth quarter of 2025. These plans are contingent upon deal closure and the company s performance under a transition services agreement. Analyzing the recent increase in Current Liabilities and its impact on Seres Therapeutics Quick Ratio will provide us with important insights into the company s financial health and stability.

1. Capital Infusions and Debt Retirement:
Through a series of anticipated capital infusions, including an upfront payment, Seres Therapeutics aims to effectively retire its debt burden. This strategic move will alleviate the financial strain on the company and allow it to focus on its core business operations and growth prospects. By reducing debt, Seres Therapeutics can allocate its resources more efficiently towards advancing its innovative microbiome therapies.

On the trailing twelve months basis In spite of the year on year decrease in MCRB's Current Liabilities to $20.03 millions, cumulative Quick Ratio to 1.71 below the MCRB average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 432 other companies have achieved higher Quick Ratio than Seres Therapeutics Inc . While Quick Ratio overall ranking has improved so far to 3849, from total ranking during the twelve months ending first quarter 2026 at 3916.

Explain Quick Ratio?
How much Cash & cash equivalents MCRB�s has?
What are MCRB�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 433
Healthcare Sector	# 885
Within the Market	# 3849

trailing twelve months Quick Ratio Statistics
High	Average	Low
11.1	2.26	0.9
(Dec 31 2015)		(Dec 31 2024)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Ardelyx inc	2.13	$ 281.830 Millions	$ 132.220 Millions
Oragenics Inc	2.12	$ 3.864 Millions	$ 1.822 Millions
Pacira Biosciences inc	2.06	$ 251.031 Millions	$ 122.011 Millions
Genelux Corporation	2.05	$ 29.870 Millions	$ 14.590 Millions
Opko Health Inc	2.01	$ 300.761 Millions	$ 149.367 Millions
Corcept Therapeutics Inc	2.00	$ 308.197 Millions	$ 153.802 Millions
Clene Inc	2.00	$ 9.700 Millions	$ 4.852 Millions
Blue Water Vaccines Inc	2.00	$ 5.942 Millions	$ 2.974 Millions
Vertex Pharmaceuticals Inc	1.99	$ 7,852.400 Millions	$ 3,937.900 Millions
Metavia Inc	1.99	$ 12.636 Millions	$ 6.346 Millions
Connect Biopharma Holdings Limited	1.93	$ 31.500 Millions	$ 16.301 Millions
Amarin Corp Plcuk	1.92	$ 314.850 Millions	$ 164.195 Millions
Mustang Bio inc	1.91	$ 15.150 Millions	$ 7.918 Millions
Therapeuticsmd Inc	1.84	$ 9.189 Millions	$ 5.003 Millions
Fortress Biotech Inc	1.81	$ 196.576 Millions	$ 108.829 Millions
Maravai Lifesciences Holdings Inc	1.77	$ 70.091 Millions	$ 39.519 Millions
Decoy Therapeutics Inc	1.77	$ 8.289 Millions	$ 4.680 Millions
Hyperion Defi inc	1.75	$ 9.637 Millions	$ 5.509 Millions
Verastem Inc	1.75	$ 136.400 Millions	$ 78.130 Millions
Urogen Pharma Ltd	1.74	$ 108.000 Millions	$ 61.915 Millions
Pyxis Oncology Inc	1.72	$ 47.141 Millions	$ 27.474 Millions
Ernexa Therapeutics Inc	1.71	$ 5.028 Millions	$ 2.932 Millions
Lantern Pharma Inc	1.70	$ 7.361 Millions	$ 4.323 Millions
Nuvectis Pharma inc	1.67	$ 22.160 Millions	$ 13.294 Millions
Quoin Pharmaceuticals Ltd	1.63	$ 10.800 Millions	$ 6.613 Millions
Mallinckrodt Plc	1.63	$ 1,075.800 Millions	$ 660.600 Millions
Macrogenics Inc	1.59	$ 173.305 Millions	$ 108.815 Millions
Fibrobiologics Inc	1.59	$ 3.515 Millions	$ 2.213 Millions
Sarepta Therapeutics Inc	1.57	$ 788.489 Millions	$ 502.908 Millions
Revium Rx.	1.55	$ 1.506 Millions	$ 0.971 Millions

Date modified: 2026-09-10T16:17:22+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.